A phase 1 study to evaluate the dose, safety and tolerability of a radionuclide therapy (Radspherin®) in patients with platinum sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma with peritoneal carcinomatosis following complete surgical resection

2024-511851-16-00 Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Sep 2024 · End 8 Sep 2025 · Status Ended · 3 EU/EEA countries · 4 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 40
Countries 3
Sites 4

Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis

Key facts

Sponsor
Oncoinvent ASA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
20 Sep 2024 → 8 Sep 2025
Decision date (initial)
2024-09-20
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511851-16-00
EudraCT number
2018-002802-29
ClinicalTrials.gov
NCT03732768

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncoinvent ASA

Sponsor organisation
Oncoinvent ASA
Address
Gullhaugveien 7
City
Oslo
Postcode
0484
Country
Norway

Scientific contact point

Organisation
Oncoinvent ASA
Contact name
Information Desk

Public contact point

Organisation
Oncoinvent ASA
Contact name
Information Desk

Locations

3 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 10 1
Norway Ended 18 1
Spain Ended 12 2
Rest of world 0

Investigational sites

Belgium

1 site · Ended
UZ Leuven
Gynaecological Oncology, Herestraat 49, 3000, Leuven

Norway

1 site · Ended
Oslo University Hospital HF
Department of Gynaecological cancer, Montebello, Ullernchausséen 70, Oslo

Spain

2 sites · Ended
Clinica Universidad De Navarra
Dept. Ob-Gynecology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Clinica Universidad De Navarra
Dept. Ob-Gynecology, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-09-20 2025-09-08 2024-09-20 2024-09-20
Norway 2024-09-20 2025-09-01 2024-09-20 2024-09-20
Spain 2024-09-20 2025-08-26 2024-09-20 2024-09-20

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-29 Norway Acceptable
2024-09-20
2024-09-20
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-09 Norway Acceptable
2024-09-20
2025-05-09